BCG treatment for bladder cancer is one of the earliest and most successful examples of cancer immunotherapy. In this presentation, Priyanka Yolmo (PhD Student at the Queen’s University Cancer Research Institute) addresses the history of Bacillus Calmette-Guerin (BCG), how it is used as a treatment for bladder cancer, as well as some current developments in the usage of this immunotherapy.
The History of BCG Treatment and Its Origins
Bacillus Calmette-Guérin (BCG) was developed in the early 1900s by Dr. Albert Calmette and Dr. Camille Guérin. Derived from a weakened form of Mycobacterium bovis, the BCG vaccine was first used in humans in 1921 to prevent tuberculosis. Over time, researchers noticed that people exposed to tuberculosis appeared to have lower rates of certain cancers, sparking interest in the immune-stimulating effects of BCG.
This growing body of research laid the groundwork for using BCG immunotherapy for bladder cancer, marking one of the earliest connections between the immune system and cancer treatment.
BCG Treatment for NMIBC and Intravesical Therapy
The modern use of BCG treatment for NMIBC began in the early 1970s, when Dr. Alvaro Morales introduced intravesical BCG therapy, delivering BCG directly into the bladder after tumor removal. This localized approach allows BCG to activate the immune system at the tumor site, reducing the risk of recurrence and progression.
Today, intravesical BCG therapy is considered the gold standard for patients with intermediate- and high-risk NMIBC, using carefully timed induction and maintenance schedules.
How the BCG Vaccine and Bladder Cancer Are Connected
Unlike vaccines that prevent disease, the BCG vaccine and bladder cancer connection lies in BCG’s ability to trigger a strong immune response. BCG immunotherapy for bladder cancer activates both innate and adaptive immune pathways, helping the body recognize and destroy cancer cells. While researchers continue to study the exact mechanisms, decades of clinical evidence support its effectiveness.
Current Challenges and Advances in Bladder Cancer Treatment
BCG shortages, treatment intolerance, and strain differences have led to ongoing research into alternative formulations, new delivery methods, and combination of therapies. These advances aim to strengthen outcomes while preserving access to BCG treatment for bladder cancer worldwide.
Support, Education, and Advocacy with Bladder Cancer Canada
Understanding treatment options like BCG immunotherapy for bladder cancer empowers patients and caregivers to make informed decisions. Bladder Cancer Canada offers trusted education, webinars, patient guides, and advocacy initiatives to support those affected by bladder cancer. Connect with Bladder Cancer Canada to access reliable resources, learn about emerging treatments, and join a community dedicated to improving bladder cancer care and outcomes.
